Efanesoctocog Alfa

5 trials 2 recruiting BHaematology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

2 Sponsors

15 Countries

Phase III

Phase IV

Phase III: 3 Phase IV: 2

Sponsors using this IMP

Swedish Orphan Biovitrum AB (publ) 4 GWT-Tud GmbH 1

All trials

5 total

Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining Pending

2025-523896-44-00 Phase III 2 countries GWT-Tud GmbH
Study to provide continued access to treatment for patients completing a previous trial with efanesoctocog alfa Recruiting

2023-506537-29-00 Phase III 10 countries Swedish Orphan Biovitrum AB (publ)
Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting

2024-517812-31-00 Phase IV 8 countries Swedish Orphan Biovitrum AB (publ)
A study to investigate the course of synovial hypertrophy in patients with haemophilia A on efanesoctocog alfa prophylaxis Ended

2024-512066-33-00 Phase IV 4 countries Swedish Orphan Biovitrum AB (publ)
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly… Ended

2022-500275-31-00 Phase III 14 countries Swedish Orphan Biovitrum AB (publ)

Showing 1–5 of 5 trials

← All drugs A–Z